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Intensity modulated radiation therapy IMRT poses a number of challenges for properly measuring
commissioning data and quality assurance QA radiation dose distributions. This report provides a
comprehensive overview of how dosimeters, phantoms, and dose distribution analysis techniques
should be used to support the commissioning and quality assurance requirements of an IMRT
program. The proper applications of each dosimeter are described along with the limitations of each
system. Point detectors, arrays, film, and electronic portal imagers are discussed with respect to
their proper use, along with potential applications of 3D dosimetry. Regardless of the IMRT tech-
nique utilized, some situations require the use of multiple detectors for the acquisition of accurate
commissioning data. The overall goal of this task group report is to provide a document that aids
the physicist in the proper selection and use of the dosimetry tools available for IMRT QA and to
provide a resource for physicists that describes dosimetry measurement techniques for purposes of
IMRT commissioning and measurement-based characterization or verification of IMRT treatment
plans. This report is not intended to provide a comprehensive review of commissioning and QA
procedures for IMRT. Instead, this report focuses on the aspects of metrology, particularly the
practical aspects of measurements that are unique to IMRT. The metrology of IMRT concerns the
application of measurement instruments and their suitability, calibration, and quality control of
measurements. Each of the dosimetry measurement tools has limitations that need to be considered
when incorporating them into a commissioning process or a comprehensive QA program. For
example, routine quality assurance procedures require the use of robust field dosimetry systems.
These often exhibit limitations with respect to spatial resolution or energy response and need to
themselves be commissioned against more established dosimeters. A chain of dosimeters, from
secondary standards to field instruments, is established to assure the quantitative nature of the tests.
This report is intended to describe the characteristics of the components of these systems; dosim-
eters, phantoms, and dose evaluation algorithms. This work is the report of AAPM Task Group
120. © 2011 American Association of Physicists in Medicine. DOI: 10.1118/1.3514120
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I. DIFFERENCES IN DOSIMETRY REQUIREMENTS
BETWEEN CONVENTIONAL RADIATION
THERAPY AND IMRT
I.A. Dose distribution complexity
The complex three-dimensional 3D shapes of intensity
modulated radiation therapy IMRT dose distributions and
the methods for IMRT dose delivery demand that the dosim-
etry measurement techniques typically employed for conven-
tional three-dimensional conformal radiation therapy
3DCRT, including straightforward dynamic techniques
such as conformal arc and dynamic wedge, be reviewed and
adapted for the unique challenges posed by IMRT. The com-
plex shape of the dose distribution leads to numerous regions
containing steep dose gradients, even within target volumes.
Understanding the limitations and use of dosimeters to mea-
sure these dose distributions is critical to safe IMRT imple-
mentation.
Conventional 3DCRT treatment planning typically utilizes
a beam’s eye view approach. Validation of 3DCRT treatment
plans can be accomplished utilizing traditional dosimetry
techniques, such as scanning ionization chambers and moni-
tor unit MU verification calculations, because these plans
are composed of superpositions of relatively large, low flu-
ence gradient, radiation segments. However, IMRT treat-
ments involve the delivery of complex dose distribution
shapes that place steep dose gradients near critical structures
in an optimized 3D configuration. The use of fluence modu-
lation allows the radiation beam orientations to be decoupled
from the tumor and critical structure geometries so that ra-
diation beams can be aimed directly through critical struc-Medical Physics, Vol. 38, No. 3, March 2011tures and the fluence modulation optimization process will
limit the critical structure doses. Unlike 3DCRT, in IMRT
portal images cannot be used to validate critical structure
avoidance. The 3D complexity of the dose, along with the
decoupling of the beam geometry and the resulting dose,
means that the quality assurance QA of IMRT dose distri-
butions needs to concentrate more on the cumulative deliv-
ered dose rather than on the QA of individual segments, as
well as checking the dose at multiple locations.
The dose gradients in the IMRT dose distributions are
intended to match the patient’s target and normal organ ge-
ometry. Not only are the relative gradient positions important
to validate, but the absolute positions also need to be veri-
fied. The IMRT dose QA measurements need to explicitly
include a quantitative registration process for independently
validating the spatial location of the dose gradients. Such a
registration process could involve the use of fixed landmarks
on the phantom that are colocated with radiopaque markers
such that alignment of the phantom to the linear accelerator
coordinate system using the positioning lasers can be regis-
tered with the alignment of the phantom in the treatment
planning system.
I.B. Temporal nature of IMRT dose delivery and its
impact on absolute dosimetry
In most 3DCRT procedures, the radiation beam is static,
meaning that beam modifiers and the gantry, collimator, and
couch remain stationary during irradiation. Because the ra-
diation beam is static, characterization of the radiation beam
can be conducted by scanning ionization chambers in water
phantoms, using interpolation when necessary to fill in the
spaces between the measured points. The dosimetric accu-
racy of ionization chambers allows for a quantitative mea-
surement of the radiation beam. While it is impractical dur-
ing 3DCRT planning system commissioning to measure
every clinically used beam configuration, the measurement
of a subset of beams is sufficient.1 IMRT dose delivery is
often a dynamic process where the incident fluence shape
and intensity are varying during the treatment, so scan-based
dose measurements become impractical. Therefore, dose
measurements of IMRT treatment plans are limited to inte-
grating dosimetric techniques.
Absolute dosimeters are defined here as those whose re-
sults, for absorbed dose to water, require no adjustment or
renormalization other than those done in accordance with the
established dosimetry protocols e.g., TG 51. As an ex-
ample, a small-volume ionization chamber is typically cross-
calibrated, in the beam quality in question, against an ioniza-
tion chamber with a NIST-traceable calibration. The cross-
calibrated ionization chamber is then used to measure
absorbed dose e.g., in Gy without the need for any renor-
malization other than for temperature and pressure correc-
tions. Factors such as nonuniformity, energy dependence,
and response instability exclude some dosimetry systems
from being used for absolute dosimetry. Recommendations
for the specific use of dosimetry systems are provided in this
report.
1315 Low et al.: IMRT dosimetry tools 1315I.C. Monitor units
Computational MU checks of 3DCRT treatment plans are
the standard of practice for MU validation. These MU checks
often use portal shape approximations to determine the re-
quired photon radiation scatter parameters. In conventional
3DCRT, these parameters change slowly with respect to the
field size and depth, and field-dependent approximations
yield MU calculations that are accurate to within a few
percent.2,3 This accuracy is considered adequate by the radia-
tion therapy community and is one method used to avoid
catastrophic clinical errors.
For IMRT dose delivery sequences, either dynamic or
static, the dose at any given location within the target volume
is delivered by a fraction of the total segments in a field. The
number of MUs required to deliver the dose distribution will
be a strong function of a complex leaf delivery sequence and
is therefore unpredictable based on only the target dose and
patient geometry. A qualified medical physicist can no longer
judge whether the number of MUs is correct based on pro-
fessional knowledge and experience, so catastrophic errors
may not be caught without an independent, quantitative vali-
dation mechanism. Either direct dose measurements, con-
ducted using phantoms, or independent dose calculation soft-
ware, is required to validate the treatment planning output on
a patient-specific basis. Independent dose calculation meth-
ods sometimes called monitor unit calculation methods
have been developed and are being used in many centers as a
component of the patient-specific QA program.4–15 Dose cal-
culation methods will continue to evolve and their role in
patient-specific QA is likely to expand. One limitation of
such independent dose calculation methods is that the deliv-
erability of the IMRT plan is not validated on the actual
treatment device. For this reason, patient-specific validation
is often conducted using direct dose distribution measure-
ments in homogeneous solid media.
I.D. Summary
The greater need for dose-measurement-based validation,
coupled with their greater dose distribution complexity and
the temporal nature of dose delivery, led to this review of
dose measurement systems for IMRT. In this report, we will
describe the uses and pitfalls of the most relevant dosimetry
systems and highlight the unique influence of IMRT on their
use. We will also provide recommendations for proper opera-
tions of specific dosimeters.
There are also other task group reports that are relevant to
the subject of IMRT dosimetry. The Task Group 106 of the
AAPM Ref. 16 recently published a report entitled “Accel-
erator beam data commissioning equipment and procedures:
Report of the TG-106 of the Therapy Physics Committee of
the AAPM” that provided recommendations for detector se-
lection. The Task Group 119 Ref. 17 of the AAPM pub-
lished a report comparing different IMRT commissioning re-
sults using a standard treatment plan dataset and Task Group
142,18 the QA of medical linear accelerators, provides IMRT
QA recommendations.
Medical Physics, Vol. 38, No. 3, March 2011This report includes examples of commercial products.
This should not be considered an endorsement by this task




Cylindrical ionization chambers are used for point-dose
measurements in megavoltage photon radiation therapy be-
cause of their excellent stability, linear response to absorbed
dose, small directional dependence, beam-quality response
independence, and traceability to a primary calibration stan-
dard. High-spatial resolution is important for IMRT
measurements.14,19–30 Table I lists some of the commercially
available “small” volume ionization chambers and their de-
sign characteristics according to the manufacturer’s litera-
ture. All listed chambers are waterproof and designed with
air-ventilation. All of these ionization chambers have cylin-
drical symmetry, minimizing the sensitivity response varia-
tion as a function of beam entry angle when the beam central
axis is perpendicular to the chamber axis of symmetry. In
Table I, the effective length is the length of the active volume
along the axis and the effective diameter is in the radial
direction perpendicular to the axis. Unfortunately, there have
been a few published studies on the oblique-incidence re-
sponse of cylindrical ionization chambers to megavoltage
beams. If the dose distribution verification measurements in-
clude noncoplanar beams, the physicist should determine the
sensitivity of the ionization chamber in such geometries.
II.A.1.a. Volume averaging. All ionization chambers ex-
hibit some amount of volume averaging. This is due to the
fact that the collected ions are created throughout the active
chamber volume. Volume averaging will cause perturbations
in dose distribution measurements in regions with high cur-
vature large second-order spatial derivatives in the dose dis-
tributions. These typically occur in conjunction with regions
of steep dose gradients, so the effect of volume averaging is
typically associated with beam penumbra regions. Bouchard
and Seuntjens25 recently examined the perturbations in ion-
ization chamber reference dosimetry for IMRT beams and
provided a methodology for correcting the chamber response
to account for nonuniform dose distributions. Monte Carlo
dose calculations were used to determine perturbation factors
for cylindrical ionization chambers. Perturbation factors for
relatively large ionization chambers Farmer, 6 mm in diam-
eter, 23 mm length active volume in individual static and
dynamic IMRT fields were determined and found to exceed
10% in some cases.25 The sensitivity dose to the collection
air cavity per incident photon was sharply peaked at the
projected ionization chamber cavity volume boundaries. The
nonuniform dose response, coupled with the heterogeneous
photon beam fluence, was responsible for the nonunity IMRT
correction factor. They concluded that fluence-perturbation
correction factors should be employed for IMRT dose mea-
surements. A second conclusion was that one should assure
that the ionization chamber be placed in regions of relatively
T a
1316 Low et al.: IMRT dosimetry tools 1316
Medical Physics, Vol. 38, No. 3, March 2011homogeneous fluence and that the relative size of the ioniza-
tion chamber and homogeneous fluence region be deter-
mined prior to the measurement. For measurements that
check the total delivered dose, the ionization chamber should
be placed in regions of homogeneous total dose.
While Bouchard and Seuntjens25 showed that ionization
chamber measurements can yield substantial dose measure-
ment errors for IMRT beams, Low et al.24 showed that even
large ionization chambers will accurately integrate dose
across homogenous IMRT dose regions. Based on these re-
sults, we conclude that there are two main clinical scenarios
where volume averaging becomes a concern. First, when
measuring the output at the center of a small static field,
volume averaging will result in an underestimate of the ac-
tual dose. In this case, care needs to be taken to assure that
the ionization chamber is sufficiently small to accurately
measure the dose, or another, high-spatial resolution dosim-
eter be used to conduct the measurement. Second, when
measuring the profile of dose distributions with rapidly spa-
tially varying doses, the measured shape of the dose distri-
bution will be blurred by volume averaging. If an accurate
measurement of the profile shape is important, a higher spa-
tial resolution detector will be required.
Regarding the size of the ionization chamber, if the treat-
ment planning system has the capability of computing the
average dose throughout the active ionization chamber vol-
ume, the use of a larger ionization chamber will reduce the
sensitivity of the measurement to positioning inaccuracies. A
small ionization chamber dose measurement will be more
sensitive to positioning errors. However, this should not be
taken as a recommendation to place a large ionization cham-
ber in a high-dose homogenous region that is smaller than
the active chamber volume. If the treatment planning system
cannot provide the volume-averaged dose, a small ionization
chamber should be used for the measurements, and the
chamber should be placed in a region of shallow dose gradi-
ent.
II.A.1.b. Energy response. The energy response of modern
ionization chambers is flat for megavoltage photon beam do-
simetry. However, for some very small chambers, in order to
increase the ionization signal, the central electrode is made
of high-Z materials, causing significant sensitivity variations
with field size and depth. For example, the central collecting
electrode is made of steel in both the PTW PinPoint™ and
the Wellhofer/Scanditronix CC01 chambers. This causes
over-response to low-energy scattered photons,20 which are
abundant in large treatment fields or under heavily blocked
areas. Consequently, care should be taken when using steel-
electrode ionization chambers for IMRT dose distribution
measurements. While this problem is not specific to IMRT
dose distribution measurements, characterizing and account-
ing for the variation in sensitivity to low-energy scattered
photons is more critical for IMRT than for static open fields.
II.A.1.c. Ionization chamber stability. A properly func-
tioning ionization chamber should demonstrate stable re-
sponse over time. A quality assurance program that cross-






























































































































































































































































































































































































































































































































































































secondary standard ionization chamber should be employed.
1317 Low et al.: IMRT dosimetry tools 1317The frequency of this check should be determined by the
clinic but should be no less frequent than the calibration of
the local secondary standard.
II.A.1.d. Stem effect. Irradiating a portion of the ionization
chamber stem cable or holder can induce leakage current,
and this will perturb the collected charge. Because the signal
from a small-volume ionization chamber is much weaker
than in a large-volume ion chamber, the relative stem effect
may be more significant. The stem effect for small ionization
chambers has not been well studied in the current literature.
The impact of this effect on IMRT dose measurements, es-
pecially in low-dose regions, has not been quantified.
II.A.1.e. Acceptance testing. New ionization chambers
need to be tested for appropriate performance. These tests
should be performed before a calibration is obtained for the
chamber. The following suggested tests are adapted from
Humphries and Purdy:31
1 Perpendicular radiographs are taken to verify that the
chamber is mechanically sound, comparing with me-
chanical design drafts if possible.
2 Leakage current should be measured to ensure that the
chamber has a sufficiently low background and that any
guard electrodes are performing properly. A bias voltage
of 300–350 V should yield at most 1–510−14 A af-
ter a few minutes from turn on or irradiation.
3 Stem effect should be quantified by irradiating the ion-
ization chamber at orientations that include and exclude
the guarded portions of the chamber.2 If the guard elec-
trodes are properly working, there should be a negligible
difference in readings.
4 Microphonics currents generated by mechanically flex-
ing the cables should be tested in the chamber as well
as the cables and connectors that will be used with the
ionization chamber. The system should be placed under
stress that is similar to any scanning motion and flexing
that can exist during phantom measurements. Triaxial
cables with a Teflon dielectric are preferred.
5 Radiation equilibration time should be measured. A
properly working ionization chamber should provide re-
producible measurements after at most two readings of
approximately 200 cGy each.
6 Atmospheric communication should be tested by check-
ing that the chamber obeys ideal gas law scaling of sen-
sitivity by mildly changing the temperature of the sys-
tem. Severe temperature changes can cause
condensation inside the chamber or possible thermal
damage cracking of plastics.
7 Polarity effects should be determined to be small




Scanditronix Filtered photon field diode PFD 
Unfiltered stereotactic field diode SFD 
PTW Diamond detector 60003Medical Physics, Vol. 38, No. 3, March 20111% for a properly working ionization chamber with
sound cables. For example, AAPM Task Group 51 states
that the polarity effect for a 6 MV beam is unlikely to
exceed 0.3%.
8 Collection efficiency should be measured. The recombi-
nation factors of the ionization chamber in the intended
radiation fields for calibration should be small definitely
1.02 and typically 1.015 so that accurate correc-
tions can be made.
9 Orientation dependence needs to be determined and
checked against specifications given by the manufac-
turer. Orientation sensitivity can limit the utility of the
ionization chamber.
II.A.2. Solid state dosimeters
p-type semiconductor diode detectors have some attrac-
tive characteristics for megavoltage photon beam dosimetry,
especially for small-field measurements. Table II lists some
of the commercially available megavoltage diodes and their
main characteristics. Diode detectors usually have very small
active volumes and high sensitivity to radiation. Comparing
Table II with Table I reveals that not only is the active vol-
ume of diodes much smaller than the smallest ionization
chamber but also the sensitivity of these diodes can be 20–
100 times greater.
The relatively high atomic number of silicon in the diode
detector will lead to a greater sensitivity to low-energy pho-
tons. Therefore, diode detectors are usually used for small-
field dose distribution measurements where there are rela-
tively few low-energy photons.32–34 Sometimes, low-energy
filters, also known as shields, are included in the diode con-
struction to minimize the low-energy sensitivity. These are
termed energy-compensated diode detectors.35 While these
diodes have been shown to have good energy response for
on-axis measurements, their use has not been verified for
off-axis radiation field measurements.
Diode detector response also exhibits orientation depen-
dence. For beams entering perpendicular to the diode axis,
the magnitude of this directional dependence is about 3%.32
However, when the beam is oriented near the diode axis, the
diode sensitivity can vary by as much as 15% Technical
Data Sheet, photon field diode detector, IBA Dosimetry. In
addition to the directional dependence, some reports also in-
dicated long-term irreversible radiation damage that changes
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1318 Low et al.: IMRT dosimetry tools 1318ommended that diodes be used only for relative dose mea-
surements and that care should be taken when selecting di-
ode orientation.
In contrast to silicon diode detectors, diamond detectors
are almost soft-tissue equivalent in terms of atomic compo-
sition although they have a physical density much greater
than water at 3.5 g cm−3, exhibit a small directional depen-
dence, have good mechanical stability, and high radiation
hardness21,35,41–43 lack of radiation sensitivity variation due
to irradiation. Similar to silicon diodes, diamond detectors
also exhibit high radiation sensitivity. Bucciolini et al.21
demonstrated that diamond detectors can produce clinically
identical results as p-type silicon diodes for small treatment
fields. However, dose-rate dependence may affect the ability
of using diamond detectors for scanning or for measurements
of IMRT dose distributions.21
Recently, chemical vapor deposition CVD diodes have
been investigated for radiation therapy dosimetry.44–54 A Eu-
ropean Integrated Project IP called MAESTRO Methods
and Advanced Equipment for Simulation and Treatment in
Radiation Oncology, http://www.maestro-research.org/
index.htm is developing a range of new tools for providing
dose measurements and the group is concentrating on IMRT
dose validation. One of their development efforts is to exam-
ine diamond detectors as quantitative radiation dosimeters.
Another type of small-field dosimeter that has been used
in IMRT is the thermoluminescence dosimeter TLD.55–68
TLD dosimetry has been used since the 1970s to quantify
megavoltage x-ray dosimetry.69–73 A TLD is an integrating
dosimeter, which is usually small in size, often in the form of
a cubical or cylindrical chip, and has a nearly tissue-
equivalent atomic composition Z=8.1 and a typical physi-
cal density of 2.6 g cm−3. Typical TLDs can exhibit nonlin-
ear integrated dose response, which must be evaluated before
use,74 along with some energy response variations. The en-
ergy response variation is sufficiently large to require that the
sensitivity calibration should be conducted using the same
megavoltage beam energy as the experiment. TLD imple-
mentation is labor intensive, so it is typically employed
where ionization chamber measurements are impractical, for
example, in multiple anthropomorphic phantom dose mea-
surements. To achieve dose measurement precision on the
order of 2%–3%, a TLD implementation program requires a
rigorous annealing and response measurement protocol, and
routine QA of the TLD reader and annealing oven tempera-
ture control.75








CNMC Reference electrometer 206 0.2 0.05
Modified Keithley 602 K602 0.1 0.10
PTW UNIDOS T10005 0.5 0.50
Wellhofer Reference electrometer DOSE 1 0.2 0.25Medical Physics, Vol. 38, No. 3, March 2011II.A.3. Electrometer and cable performance
The basic requirements for electrometers are 1 accuracy,
2 linearity, 3 stability, 4 sensitivity, 5 high impedance,
and 6 low leakage. Table III lists some of the performance
data of modern electrometers according to vendors’ litera-
ture. These electrometers have much lower leakage currents
than most of the older models. The leakage for ionization
chambers shown in Table I is comparable to the electrom-
eters’ leakage.
With respect to small ionization chambers used for IMRT,
the performance of the read-out electrometer becomes more
important as the ionization chamber volume is reduced. The
fraction of integrated charge due to cable and electrometer
leakage is inversely proportional to the charge collected by
the chamber and is proportional to the amount of time re-
quired for the measurement. In IMRT dose measurements,
the dose integration time is often significantly longer than for
conventional measurements.76–81 A large fraction of the de-
livered dose is due to collimator and linear accelerator head
leakage, so the dose needs to be measured for all beams,
even those radiation beams that do not directly intercept the
ionization chamber for example, for serial tomotherapy in-
dices where the chamber position is far from the beam por-
tals.
The leakage of the chamber-cable-electrometer system
should be checked for each measurement session using the
commonly accepted leakage specification published by
Humphries and Purdy.31 It states that “Excellent, average,
and bad electrometer zero drifts are 10−15 A, 10−14 A, and
10−13 A, respectively.” The contribution of background leak-
age to the integrated charge can be approximated as a func-
tion of ionization chamber volume, integrated dose, and in-
tegration time. Assuming that the leakage current linearly
affects the resulting measured charge, the relative error in





where E is the relative measurement error, C is the charge
due to ionizations in the chamber, Il is the leakage current,
and t is the ionization integration time.
Figure 1 shows some examples using Eq. 1 applied to an
integrated dose of 200 cGy for typical ionization chamber
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0.1using ionization chambers with relatively small volumes if
1319 Low et al.: IMRT dosimetry tools 1319the measurements are expected to require several minutes of
ionization collection. For example, if an uncorrected IMRT
measurement of 200 cGy requires 10 min to acquire, using a
0.009 cm3 ionization chamber, leakages of 10−14, 510−14,
and 10−13 A will yield 1%, 5%, and 10% dose measurement
FIG. 1. Examples of fractional measured ionization collection errors due to
system leakage current for a 200 cGy IMRT dose distribution measurement
for a variety of ionization chamber volumes and system leakage currents. a
Measurement error for a 0.007 cm3 volume ionization chamber. b Mea-
surement error for a 0.009 cm3 volume ionization chamber. c Measure-
ment error for a 0.056 cm3 volume ionization chamber.errors.
Medical Physics, Vol. 38, No. 3, March 2011Physicists should also assess the performance of elec-
trometers with automatic leakage correction. The correction
feature may need to be turned off for low-dose IMRT mea-
surements so that the reported collected charge is not incor-
rectly reset during a measurement.
II.A.4. Applications to IMRT
II.A.4.a. Selection of radiation detectors for IMRT
measurements. For point-dose measurements, an ionization
chamber built from tissue- or air-equivalent materials is rec-
ommended to minimize detector over-response to variations
in the photon spectrum as a function of measurement posi-
tion. Because of the steep dose gradients and relatively large
number of small-field size segments used in IMRT plans, it is
essential that the ionization chamber have a spatial resolution
of sufficient magnitude to avoid dose measurement errors.
When comparing calculations against measurements, the cal-
culated dose can be determined either by point sampling in
the calculated dose distribution or extracting the mean ion-
ization chamber volume dose. This is typically conducted by
contouring the active chamber volume in the treatment plan
and using dose-volume statistics to determine the average
dose value. The volume-averaging process is recommended
unless it is not possible or impractical. If the volume-
averaging process is used, the ionization chamber volume
can be larger and this can reduce the sensitivity of spatial
positioning error on the measured dose.
The doses being delivered to critical structures can also be
verified using an ionization chamber. As with target volumes,
care should be taken to assure that the dose is relatively
homogeneous across the ionization chamber and that mea-
sured dose be compared against the volume-average of the
calculated dose.
II.A.4.b. Preparing for IMRT measurements. The prepara-
tion for ionization chamber measurements should include al-
lowing the ionization chamber and phantom to reach equilib-
rium temperatures e.g., the treatment room temperature and
orienting and localizing the chamber and phantom accurately
with respect to the linear accelerator. Better than 1 mm po-
sitional agreement with respect to the isocenter between the
measurement system and the calculated system should be
possible.
II.A.4.c. Cross-calibration of detectors prior to IMRT
measurements. Clinics typically use a Farmer-type ionization
chamber as the local secondary standard. A local cross-
calibration procedure to assess the IMRT ionization chamber
response should be established prior to performing IMRT
measurements. For example, Dong et al.14 described a cross-
calibration procedure that used lateral parallel-opposed 10
10 cm2 fields to monitor the linear accelerator output
variation at the time of measurement. Another approach is to
determine an ionization chamber and electrometer sensitivity
factor using a calibrated radiation beam and then to use the
measured sensitivity factor for subsequent IMRT QA proce-
dures. This approach will provide dose measurements that
are sensitive to the daily linear accelerator output fluctua-
tions. This procedure should be conducted no less often than
the calibration of the local secondary standard.
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errors can occur if small-field output measurements are con-
ducted with large-volume ionization chambers. Small-
volume ionization chamber measurements without volume-
averaging corrections should be used for field sizes between
22 and 55 cm2 such that the field sizes are 1.5 cm
wider than the effective length of the ionization chamber.
Correction techniques, such as the deconvolution method,
have been used to obtain accurate relative output measure-
ments using small-volume ionization chamber
measurements,22,82–84 but they are not in widespread use. For
larger field sizes, standard-volume ion chambers can be used.
Alternatively, radiographic or radiochromic film or diodes
can be used to determine the output factors for very small-
field sizes.85–89
II.A.4.e. Profile and central axis depth-dose
measurements. IMRT treatment planning systems require
profile and depth-dose measurements as input for modeling
and verification. Photon beam profiles have steep dose gra-
dients and, consequently, the spatial resolution of the mea-
suring detector can profoundly affect the measured profile
accuracy. Even small-volume ionization chambers will arti-
ficially broaden the measured penumbra shape due to volume
averaging.16,20 Using the ionization-chamber measured pen-
umbra in the treatment planning system modeling process
may cause errors in subsequent IMRT dose calculations and
MLC leaf sequences.90,91 High-spatial resolution measure-
ment systems effective resolution 1 mm, such as radio-
graphic and radiochromic film coupled with quantitative film
densitometers, or scanning diodes, will provide sufficiently
accurate measurements of the penumbra shape for treatment
planning system dose modeling.
Aside from radiochromic film, the high-spatial resolution
detector systems have non-water-equivalent energy response.
The measurements using these systems will be more accurate
if they are confined to relative measurements where the beam
energy spectrum does not vary significantly within the mea-
sured distribution. The photon energy spectrum changes suf-
ficiently with respect to depth for central axis depth doses,
for example, so that the energy response of the non-water-
equivalent detectors can cause measurement errors. There are
also ionization chambers that have non-water-equivalent re-
sponse. An example is the steel-electrode PinPoint ionization
chamber Table I dose response reported by Martens et al.20
While this ionization chamber provided excellent profile
measurements, the steel electrode caused energy response
variations that made the chamber unsuitable for output factor
measurements or depth-dose measurements. Recently, Ago-
stinelli et al.92 reported the energy response for a new ver-
sion of the PinPoint ionization chamber with an aluminum
electrode. When a polarity correction measurement was
used, the ionization chamber response varied less than 0.5%
for field sizes from 22 to 4040 cm2. It is incumbent on
the physicist to conduct the sensitometric measurements at
depths and field geometries that most closely match the pro-
file measurement conditions so that differences in the photon
spectrum yield insignificant sensitivity differences.
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1 Ionization chambers
a Ionization chambers should be used:
i In homogeneous dose regions
ii To verify monitor unit outputs
iii To verify critical structure doses.
b Ionization chambers should not be used:
i To measure beam profiles that will be em-
ployed to model the IMRT beam penumbra.
ii When the leakage current will yield an inte-
grated charge of 5% of the expected
radiation-induced charge. Leakage current
corrections should be applied if the expected
uncorrected error is 2%.
c Chamber selection
i A cylindrical ionization chamber should be
used.
ii The size of the ionization chamber should be
appropriate for the task
1 For measuring output factors: The radia-
tion field should be 1.5 cm wider than
the effective length of the ionization
chamber.
2 For IMRT dose measurements: The ion-
ization chamber size should be small
enough to limit the dose heterogeneity
across the chamber active volume to
10% and 5% if the measurements are
being compared against volume-
averaged and point doses, respectively.
iii The ionization chamber electrode should be
fabricated out of low-Z materials e.g., alu-
minum. When high-Z electrodes are used,
the chamber should be cross-calibrated in
conditions that minimize photon spectral dif-
ferences e.g., the same depth and minimiz-
ing field size differences.
d Measurement protocols
i When ionization chambers are used to vali-
date single-point IMRT absolute doses:
1 The ionization chamber should be
placed in a region of the dose distribu-
tion where the expected dose heteroge-
neity is less than 10% or 5% across the
ionization chamber and the expected
dose heterogeneity is less than 10%
within 2 mm from the intended ioniza-
tion chamber position, if the measure-
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volume-averaged or point doses, respec-
tively.
2 While point-dose comparisons are pos-
sible with all treatment planning sys-
tems, the measured dose should be com-
pared to the calculated doses that have
been averaged throughout the active
ionization chamber active volume. This
is typically done by computing the dose
using a CT scan with the ionization
chamber in place, contouring the ioniza-
tion chamber volume, and querying the
treatment planning system dose statis-
tics for the mean dose. This system can
also be used to identify the expected
dose heterogeneity.
2 Diode detectors single-point detectors
a Diode detectors should be used:
i For measuring relative dose distributions,
particularly for measuring MLC penumbras
used in beam modeling in a treatment plan-
ning system
ii For providing dose measurement points
supplemental to ionization chamber
measurements
b Diode detectors should not be used:
i To measure absolute doses
ii As the sole measurement device for measur-
ing beam profiles that will be employed to
model the IMRT beam penumbra. This is
due to the potential for over-response in the
low-dose regions outside the field bound-
aries. Other detectors with little energy re-
sponse variations should be compared to
diode-measured profiles to assure that the di-
ode profile provides accurate out-of-field
results.
c Diode selection
i Use unshielded diode detectors
ii Diode detectors designed for in vivo dosim-
etry should not be used for in-phantom
measurements.
d Measurement protocols
i Diode response varies with orientation, so
the relative orientation of the diode to the
radiation beam should be carefully
considered.
3 Thermoluminescent dosimeters chipsa TLD detectors should be used:
Medical Physics, Vol. 38, No. 3, March 2011i When the phantom geometry will not allow
ionization chamber measurements.
ii When multiple simultaneous point measure-
ments are desired.
b TLD detectors should not be used:
i To measure absolute doses if the overall
measurement precision needs to be better
than 3%
c TLD selection
i Low-atomic number TLDs e.g., LiF should
be used.
d Measurement protocols
i A strict annealing and calibration protocol
should be adopted that provides relative re-
sponse factors for individual chips.
ii Care should be taken to assure that the user
accurately knows the TLD positions with re-
spect to the linear accelerator.
II.B. Two-dimensional dosimetry
While point dosimetry allows for absolute IMRT dose dis-
tribution validation at individual points, thorough validation
and quality assessment of IMRT dose distributions requires
higher dimensional measurements. The current commercial
options for two-dimensional 2D dosimetry are radiographic
film, radiochromic film, computed radiography, diode arrays,
and ionization chamber arrays.
II.B.1. Film
II.B.1.a. Silver halide film. This section describes the rela-
tive 2D radiographic film dosimetry techniques for IMRT
validation and quality assurance. A report from the American
Association of Physicists in Medicine AAPM Task Group
69 on radiographic film for megavoltage beam dosimetry
comprehensively addressed all aspects of radiographic film
dosimetry and we refer the reader to this document for a
more detailed discussion.93
Although radiographic film has been demonstrated to be
capable of effectively validating 2D IMRT dose distributions
in phantoms, there are many important considerations and
potential pitfalls in using this technique. These include varia-
tions in film sensitivity caused by film batch, processor con-
ditions, variations in photon beam spectrum throughout the
measured dose distribution, and densitometry artifacts. Of
these variables, the one that has the greatest potential for
causing dosimetry errors is the variation in optical density
OD with film processor developer temperature TG 69 and
Bogucki et al.94.
When considering the trade-off between experimental
complexity and labor and the information obtained, radio-
graphic film provides an attractive measurement technique.
Radiographic film dosimetry is convenient to employ be-
cause high quality, automated film-processing equipment is
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matched with the appropriate densitometer, film is an excel-
lent tool for 2D dose mapping due to its extremely high-
spatial resolution with grain sizes typically having dimen-
sions on the order of microns.
II.B.1.b. Radiochromic film. Unlike radiographic film, ra-
diochromic film is nearly tissue-equivalent and does not re-
quire a processor for generating the optical density response
to ionizing radiation. An AAPM Task Group TG 55 Ref.
95 reported on the use of radiochromic film for dosimetry
measurements. Until recently, most of the experience using
radiochromic film was based on Gafchromic MD-55 and HS,
which were relatively insensitive to radiation.86,87,96–103 The
dose sensitivity was too low for the film to be practical for
routine clinical IMRT measurements. Recently, a high-
sensitivity radiochromic film Gafchromic EBT was intro-
duced that has OD sensitivity similar to the radiographic
Kodak EDR-2 film.104–112 The current fabrication process for
EBT film places the radiation sensitive layer within the sub-
strate in such a way that the measured OD can be a strong
function of the film orientation.113 Laser densitometers are
not recommended for use with the film because the crystal-
line structure for this type of film has changed from that of
previous films, causing polarization artifacts and lead to a
steep orientation dependence of OD response.114 Initial in-
vestigation of fluorescent lamp-based flatbed scanners with
the new film yielded promising results.84,115 Published works
indicate that there are three significant artifacts that can limit
the accuracy of Gafchromic EBT read out on flatbed
scanners.113,114,116 The first effect is a film rotation effect that
depends on the orientation of the film on a flatbed scanner
bed. The second involves scanner uniformity, and the third
depends on the temperature of the scanner bed while scan-
ning. In spite of these limitations, radiochromic film is the
only available alternative for high-spatial resolution 2D dose
measurements for clinics that have not retained or installed
radiographic film processors.
Potential users of EBT film should be aware that clinical
implementation of radiochromic film poses additional chal-
lenges that differ from radiographic film. The current formu-
lation of EBT film utilizes a hydroscopic emulsion that
causes variation in sensitivity immediately after the films are
cut, typically done to place them in a phantom or to prepare
for a sensitometric measurement. Some cutting techniques
cause more shearing that leads to greater film edge artifacts,
so the user should develop a cutting technique that mini-
mizes shearing.
At typical dose levels, the pixel-to-pixel measurement
noise is greater than other dosimetry techniques in radiation
therapy. For data used in the measurement of beam profiles
or output factors, the dose to the film can be increased such
that the noise is relatively small. When radiochromic film is
used to measure clinical IMRT dose distributions in low-dose
regions, or to characterize low-dose features such as penum-
brae tails, the pixel-to-pixel noise may limit the measurement
precision. Methods such as pixel averaging can be used to
reduce the noise, but caution should be taken to assure that
these methods do not introduce errors in the measured doses.
Medical Physics, Vol. 38, No. 3, March 2011As with other film methods, all films within an experiment
should be consistently handled, for example, storage condi-
tions, time between irradiation and scanning, and orientation
in the scanner. The sensitivity to humidity has not yet been
quantified and may be a significant cause of optical density
variations.
The manufacturer recently developed a new formulation
and markets it as EBT-2. The manufacturer claims that
EBT-2 has improved properties over the previous film, but
the user should verify its dosimetric properties prior to use.
II.B.1.c. Densitometry. After processing, films need to be
scanned to measure their response. Transmission-based opti-
cal scanners are required for good quantitative results. When
properly calibrated and characterized, commercially avail-
able 2D optical densitometers allow for the study of the steep
dose gradients found in IMRT dose distributions. For the
purposes of this report, we divide the scanner designs into
two classes. Confocal point-source scanners translate a point
source over the film, typically by translating a collimated
beam of light in concert with a confocal detector single
source focused to a detector such that measurements are
made point-by-point. This type of scanner typically has the
poorest spatial resolution with beam spot sizes between 0.25
and 0.8 mm in diameter. Sample spacing for these devices
can be typically adjusted between a fraction of the spot size
and several centimeters. Higher-dimensional scanners em-
ploy linear or area arrays of detectors and a light source.
Commercially available 2D scanners typically have pixel di-
mensions that are defined by the light source and detector
geometry. These devices have a much higher spatial reso-
lution with pixel dimensions between 0.34 and 0.042 mm.
The detectable OD for these devices typically ranges be-
tween 0 OD and an upper limit of between 2.5 and 4.0 OD,
depending on the light source and detector technology. Mea-
surements should be limited to the OD dynamic range speci-
fied by the scanner manufacture to ensure reliable results.
Before using a scanning system for film densitometry, the
response, spatial integrity, susceptibility to image artifacts,
and quality assurance protocol of the scanner should be
checked according to the recommendations of the AAPM
TG69. It is important to establish a protocol of operation so
that results are measured consistently, for example, assuring
that the scanner reaches steady-state operating conditions.
II.B.1.d. Application to IMRT. Radiographic film. Silver
halide based radiographic films, often referred to as radio-
graphic films although all dosimetry films are, in fact, radio-
graphic, have been widely used for validation of the
relative dosimetry of IMRT treatment phantom
plans.56,65,68,90,106,117–127 In principle, such measurements al-
low for the verification of the appropriate shape and registra-
tion of the IMRT dose distribution in a selected two-
dimensional plane film plane. Appropriate selection of the
orientation and locations of the film planes is important to
assure that the measured dose is useful for the desired QA
function.
The most important quantity to consider when selecting a
type of film for dosimetry is the dependence of OD on the
absorbed ionizing radiation dose, often called the sensitomet-
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manufacturers of radiographic films, including Agfa, CEA,
DuPont, Fuji, Kodak, and Konica. These companies make a
wide range of films for different applications. Currently in
the United States, the majority of clinical film dosimetry is
performed with two films from a single manufacturer: Kodak
XV2 and EDR2 film. These films differ mainly in the shape
of their characteristic curves and the speed of the films. In
order to measure an IMRT dose distribution without perturb-
ing the clinical delivery process, a film is required to accu-
rately measure doses up to the maximum delivered dose. For
dose measurements of individual fields, either Kodak XV2 or
EDR2 film is useful. For composite dose measurements of
entire IMRT dose distributions, EDR2 film is most appropri-
ate because it is the only film type with a characteristic curve
that maintains a useful sensitometric slope up to and beyond
500 cGy.121,127–129 Zhu et al.129 showed that the sensitometric
curve maintains a slope until 600 cGy, but the net OD at that
point was 3, which can cause densitometry artifacts for some
scanners. In order to allow the OD of EDR2 film to stabilize,
the film should be processed at least 1 h after irradiation.130
Radiochromic film. Because of its nearly tissue-equivalent
characteristics and well-matched dose response, radiochro-
mic film can be used to acquire accurate relative dose distri-
bution measurements.95,105,131–134 For IMRT commissioning,
radiochromic film can be used to acquire beam profiles that
will be used for modeling beam penumbra.99,133 It can also
be used to measure relative output factors for very small
fields100,133,135–137 and can be used to measure phantom-
based IMRT dose distributions, for example, dose distribu-
tion measurements that will be used to verify the treatment
planning system’s programming of the linear accelerator de-
livery parameters “monitor unit outputs”.
Although radiochromic film has a nearly linear OD de-
pendence, accurate dose measurements still require a
custom-measured sensitometric curve.99 This is typically
conducted by cutting up a piece of radiochromic film into
relatively small pieces approximately 33 cm2 and irra-
diating each piece to a different dose. Even though EBT film
is nearly tissue-equivalent, the calibration beam should be of
the same energy as the measurement energy. In order to al-
low the OD response of the film to stabilize, the film should
not be scanned less than 1 h after irradiation.99
II.B.1.e. Summary of recommendations.
1 Film
a Radiographic film
i Radiographic film should be used:
1 For relative IMRT dose distribution
measurements
2 To measure beam profiles that will be
employed to model the IMRT beam
penumbra
3 For measuring relative output factors of
small fieldsii Radiographic film should not be used:
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2 To verify monitor unit outputs
iii Film selection
1 Two commercial radiographic films are
most commonly used, Kodak EDR2 and
XV2. The selection of film should be
based on the expected maximum dose in
the film plane.
2 XV2 should not be used to measure
doses greater than 100 cGy.
3 EDR2 should not be used to measure
doses greater than 500 cGy.
iv Measurement protocols
1 A sensitometric curve should be mea-
sured for each radiographic film experi-
ment.
2 The sensitometric curve films should be
selected from the same batch as the
measurement films.
3 The sensitometric curve films should be
processed at the same time as the mea-
surement films.
4 The recommendations of AAPM Task
Group 69 should be observed for radio-
graphic film and densitometry.
5 Handle film carefully with clean hands
or light cotton gloves.
6 Bending, stretching, or scratching films
should be avoided.
7 For EDR-2, wait at least 1 h after irra-
diation before processing.
b Radiochromic film
i Radiochromic film should be used:
1 For measuring relative dose distribu-
tions
2 For measuring dose distributions that
will be used to model the IMRT beam
penumbra
3 For measuring relative output factors of
small fields
4 When a radiographic film processor is
not available
ii Radiochromic film should not be used:
1 For absolute dose measurements
2 To verify monitor unit outputs
iii Film selection
1 EBT-2 is the only film commercially
available with appropriate sensitivityiv Measurement protocols
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sured for each radiochromic film experi-
ment.
2 The sensitometric curve films should be
selected from the same batch as the
measurement films.
3 The optical density distribution should
be measured no sooner than 1 h after
irradiation
4 The sensitometric curve and measure-
ment films should be irradiated on the
same day
5 The sensitometric curve and measure-
ment films should be scanned on the
same day
6 The orientation of the sensitometric and
measurement films during scanning
needs to be consistent with respect to
the original orientation.
7 Handle film carefully with clean hands
or light cotton gloves.
8 Bending, stretching, or scratching films
should be avoided.
II.B.2. Array detectors
Array detectors calibrated to yield multiple cumulative
readings of absorbed dose across a 2D plane represent a re-
cent and popular new addition to the tools available for rou-
tine clinical IMRT QA.106,138–141 They offer the potential for
increased efficiency because, after cross-calibration, they can
be used to provide a large number of dose measurements in a
single irradiation per beam, with the results available im-
mediately after delivery. The immediacy of the results repre-
sents an attractive feature for IMRT QA as it facilitates effi-
cient diagnosis of common sources of error and estimation of
their magnitude. Examples include errors in leaf calibration
and inaccurate penumbral and small-field output factor mod-
eling by the treatment planning system. Correlating measure-
ment discrepancies that lie along the trajectory of a leaf pair
can be used to diagnose leaf-positioning errors. Existing ar-
ray detectors have low spatial resolution typically
7 mm, which limits their role to routine QA of a precom-
missioned IMRT technique. Initial commissioning should be
performed with a higher resolution system e.g., film to en-
able more thorough evaluation of the fine dose distribution
structure. A further limitation to array detectors is that al-
though each beam can be independently verified, no knowl-
edge is obtained about the composite 3D dose distribution,
resulting from the superposition of all beams. If errors are
determined in individual beams, the accumulation of all er-
rors in the 3D distribution is unknown. Significant discrep-
ancies at this stage can be investigated with planar measure-
ments in 3D phantoms Sec. II B 1. Despite these
limitations, 2D planar detector arrays have achieved wide-
spread clinical acceptance due to their convenience and effi-
ciency.Medical Physics, Vol. 38, No. 3, March 2011II.B.2.a. Description. Until recently, the only commer-
cially available two-dimensional diode array detector utilized
n-type diode technology.138,140,141 This device is called the
Mapcheck Sun Nuclear, Melbourne, FL Fig. 2. The
Mapcheck contains an array of 445 variably spaced diodes
over an area of 2222 cm2. The diode spacings are 7.07
and 14.14 mm in the central 1010 cm2 and the outer re-
gions, respectively. The diode plane has an effective build-up
depth of 2 cm and a backscattering thickness of 2.3 cm. The
physical cross section of each diode is 0.8 mm2. The diode
response is linear with dose up to saturation at 2.8 Gy. A
2% sensitivity variation has been observed when the instan-
taneous dose rate is varied by a factor of 3.140 Uncertainties
arising from these variations can be minimized by standard-
izing the SSD and repetition rates for IMRT QA.138,140
The Mapcheck is calibrated through a straightforward
process provided by the manufacturer. A relative detector
calibration is conducted first using a series of irradiations of
a static field. The detector is rotated or translated between
irradiations in a manufacturer-defined sequence. This identi-
fies the relative calibration of each detector. The second step
calibrates the Mapcheck device for absolute dosimetry by
irradiating the device to a known dose at the central axis. The
relative calibration is highly stable, and publications indicate
that it is stable for 6 months.106,138,140 The system calibration
varies with temperature at 0.5% / °C.140
Ionization chamber array detectors are also under devel-
opment in academic and commercial institutions.142–144 Re-
cently, Poppe et al.145,146 reported on two commercial ioniza-
tion chamber arrays. These have been designed and
fabricated by PTW-Freiburg. Version 1 and the model
seven29 cover an area of 2727 cm2. Version 1 has 256
detectors 1616 and model seven29 has 729 2727
ionization chambers, both arrayed in a square pattern. Ver-
sion 1 utilizes 88 mm2 cross-sectional chambers with 8
mm water-equivalent material between adjacent chambers to
isolate each chamber relative to secondary electron flux per-
turbations from neighboring chambers. The model seven29
utilizes 55 mm2 cross-sectional chambers with 5 mm
water-equivalent material between adjacent chambers. The
chambers for both version 1 and model seven29 have 5 mm
air-filled height. The short- and long-term 4 months repro-
ducibility was found to be 0.2% and 1%, respectively. The
linearity was excellent, being less than 0.4% from doses of 2
FIG. 2. Example of a matrix detector.
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agreement with conventional ionization chamber
measurements.145,146 Both arrays responded as expected with
respect to spatial resolution.
II.B.2.b. Application to IMRT. The Mapcheck device is
used to verify the absolute and relative dose distribution on a
beam-by-beam basis. The device is leveled on the couch and
irradiated at normal incidence with the gantry oriented with
the central axis pointing downward. Typically, additional
build-up material is placed on the device so that the effective
measurement plane is 5 cm or deeper. For large IMRT fields,
it may be necessary to reduce the SSD to maintain the field
within the 22 cm2 active area with an equivalent reduction
in the SSD used in the phantom treatment plan or multiple
measurements may be required with the device at different
positions. Software interpolation of the measured dose points
generates a 2D contour map of IMRT dose distribution at the
measurement depth. The user can then import the calculated
dose distribution corresponding to the same beam and depth
for comparison and analysis.
The 2D ionization chamber arrays have detector spacing
of 11 cm2, so they may not provide sufficiently high-
spatial resolution to provide isodose distributions, but each
detector point may provide a quantitative dose measurement.
Depending on the dose analysis tool employed, even with
such a relatively coarse spacing, the detector array may pro-
vide a quantitative method for evaluating IMRT dose distri-
butions. Further investigation is warranted to determine the
limitations of these arrays for IMRT QA.
II.B.2.c. Recommendations for use.
1 Useful for efficient routine QA of a precommissioned
IMRT technique. Initial commissioning should be per-
formed with a system with higher spatial resolution
e.g., film.
2 For calibration and all measurements with the device,
the linear accelerator dose repetition rate should be the
same as for the clinical treatment.
3 The device calibration should be checked monthly, or as
specified by the manufacturer or published literature.
4 Careful consideration should be given to the develop-
ment of pass/fail acceptance criteria for the evaluation of
the results from an array detector. For example, AAPM
Task Group 119 Ref. 17 demonstrated pass rates of
90% of the evaluated points when using 3 mm/3%
distance-to-agreement DTA and dose-difference crite-
ria, respectively, when reporting institution’s planar di-
ode detector measurement QA results. Each physicist
should determine acceptance criteria that are appropriate
for the treatment site, the treatment objectives, and the
clinic’s policies.
II.B.3. Computed radiography
Computed radiography CR has been available for more
than 20 years,147 but is gaining interest in radiation oncology
as a dosimeter because of the removal of film processors
from radiation oncology departments. CR uses a storage
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storage phosphors use barium, which causes the phosphors to
over-respond to low-energy photons. Also, while the systems
are used for radiology, their use as quantitative dosimeters
still has the following challenges: Response stability, reader
optical scatter, sensitivity to room light exposure, and direc-
tional response variations.148 CR techniques have been suc-
cessfully used for megavoltage beam relative dosimetry by
employing low-energy filters, but care should be taken if CR
is used for IMRT QA because the photon spectrum varies
widely across IMRT fields. CR techniques have been suc-
cessfully used for relative dosimetry of single and composite
axial plane megavoltage beam IMRT using low-energy fil-
ters for field sizes less than 1515 cm2.148
III. PHANTOMS
III.A. Phantom types
III.A.1. Phantom selection for IMRT
Verification processes for IMRT vary significantly in their
phantom requirements, with the appropriate phantom deter-
mined by the purpose of the measurement. Phantoms are
typically constructed using either water or water-equivalent
plastic.65,68,149–152 Open water phantoms can be used when
the beam is perpendicular to the phantom surface, and where
great flexibility in detector positioning is desired. With the
proper procedures and design, water-equivalent plastic phan-
toms can support multiple detectors, radiographic film, and
rapid and efficient setup reproducibility. Such phantoms can
also include the substitution or addition of heterogeneous
materials.65,150 To conduct an overall evaluation of an IMRT
delivery system, anthropomorphic phantoms are useful in
conjunction with other phantoms.
III.A.2. Geometric phantoms
Simple geometric phantoms that can accommodate ion-
ization chambers and film are used for measuring single-
point and planar doses.65,150 Cubic phantoms, comprised of
slabs, are easy and accurate to set up and allow for measure-
ments at multiple depths. The slabs can be water equivalent
or built with materials having relative electron densities rep-
resenting specific anatomical tissues. Setup accuracy is im-
proved if the phantom is scribed with setup lines whose po-
sitions are accurately known with respect to the dosimeters.
The use of fiducial marks on the film should be considered
for registration of the film with respect to the phantom. For
example, a NOMOS phantom was modified to accommodate
TLDs and multiple ionization chamber positions by using
different spacers of water-equivalent material.65 The use of
the phantom was also extended from a head-and-neck geom-
etry to a prostate geometry by construction of an outer shell
to fit over the rectangular phantom. Rectangular phantoms
are useful for measuring single field or composite dose dis-
tributions.
Cylindrical phantoms have a convenient geometry for co-
planar composite IMRT delivery verification, while allowing
153for multiple ionization chamber positions. A novel cylin-
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and an ionization chamber at the phantom center was devel-
oped for tomotherapy verification.68,151 The advantage of this
phantom is that it samples the volumetric dose distribution
with a single film, although film dosimetry analysis software
vendors have not provided software that interpolates the cal-
culated dose distributions to the coordinates of the measured
film. Another cylindrical water-equivalent phantom is pro-
vided by Tomotherapy, Inc., for the quality assurance of To-
motherapy treatments.154 There are also slab phantoms that
are machined to accept commercial ionization chambers.
III.A.3. Anthropomorphic phantoms
Anthropomorphic phantoms are fabricated in the shape of
a human and, consequently, they can be more difficult or at
least more time consuming to accurately set up and align
with respect to the linear accelerator. The preparation and
accurate placement of film can be more difficult than with
geometric phantoms. The preparation of films involves cut-
ting film to match the shape of the external phantom shape
and sealing the phantom around the film with light-tight tape
if light-sensitive films are used. In spite of the added diffi-
culty, anthropomorphic phantoms have been effectively used
for limited measurements to evaluate the process of patient
treatment planning and delivery and to identify treatment
planning or dose delivery problems that are not evident in
simple homogeneous geometric phantoms.59,155–157 The
phantom setup typically parallels a human simulation and
irradiation. For example, a CT simulation of the phantom
should be conducted using radiopaque and visible fiducial
markers, and when possible, the phantom position should be
independently verified, for example using an electronic por-
tal imaging device EPID or film at the treatment unit before
delivery.
While anthropomorphic phantoms are good for assessing
the overall IMRT planning and delivery process, many com-
mercial phantoms are composed of thick transverse slices,
which limit the flexibility in film and point-dosimeter place-
ment. Another problem is that causes of dose distribution
discrepancies are difficult to isolate using an anthropomor-
phic phantom. Therefore, additional measurements using
geometric phantoms may also be required to aid in the inter-
pretation of any discrepancies between measurements and
calculations.
III.B. Phantom materials
Phantoms should be made of a water-equivalent or known
electron-density material so that the treatment planning sys-
tem can accurately calculate dose to the phantom. A large
number of such phantoms of different shapes made of water-
equivalent materials are commercially available. When non-
water-equivalent materials such as PMMA and polystyrene
are used, validation of the dose distribution calculation algo-
rithm should be conducted before clinical use.
Additional considerations are required when radiographic
film is used. Optical and UV light will expose the film, so the
phantom must be light tight and internally opaque to prevent
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ments are typically made in homogeneous phantoms. It is
best to use a light-tight compression film phantom, although
paper packaged ready-pack film use is acceptable without a
light-tight phantom as long as the packaging is carefully
vented or adjusted to prevent trapped air bubbles and the film
package is compressed. The use of phantoms with Pb or
other high atomic number materials is not
recommended.158,159
III.C. Phantom characterization
The dimensions of a phantom should be verified prior to
first use. IMRT treatment plan validations necessarily require
the CT simulation of the phantom. These imaging data
should also be used to inspect the construction of the phan-
tom. Particular attention should be paid to flaws in the phan-
tom material such as voids. Dosimeter positions should be
identified on the CT scan study. This is especially important
for anthropomorphic phantoms, where the dosimeter posi-
tions should be localized either by visualizing the dosimeter
voids or with radiopaque dummy markers put in place of the
dosimeters. For all phantoms, delineation of larger dosim-
eters, such as ionization chambers, is necessary to compute
the volume-averaged dose. This can be done by imaging the
phantom and contouring the detector volume in the treatment
planning system as a structure of interest.
IV. DOSE DISTRIBUTION COMPARISONS AND
EVALUATIONS
This section describes published dose distribution com-
parison algorithms, their use, and their limitations when ap-
plied to IMRT. The measurements of complex dose distribu-
tions described in this report are of little value unless they
can be quantitatively compared against calculated dose dis-
tributions. The value of quantitative dose distribution com-
parisons was first identified during the photon and electron
treatment planning consortia of the 1990s. They developed a
series of tools for comparing the 3D dose distributions pro-
duce by treatment planning systems and the 2D measured
dose distributions typically interpolated from water phan-
tom data.160
With IMRT, the need for quantitative, efficient dose dis-
tribution comparison tools is even greater. IMRT requires
accurate multidimensional validation by quantitative com-
parison between measurement and calculation.
IV.A. Dose distribution registration
Dose distribution comparisons are useful only if the two
distributions have been accurately coregistered. Treatment
planning systems calculate dose in 3D and will often export
a planar dose distribution for comparison against measure-
ment. To accurately compare calculated and measured dose
distributions, the dose distribution positions should be pre-
sented in a common coordinate system.
The dose measurement phantom will have a method for
alignment with respect to the linear accelerator. That system
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namely, a set of radiopaque and visible markers that is iden-
tified on the treatment planning system prior to producing the
test treatment plan or phantom plan. Localizing the dose
measurement location for point-dose measurements e.g.,
ionization chambers may be as straightforward as using ma-
chined drawings of the phantom and knowledge of the center
of the active chamber volume. For film dosimetry, the film
should be accurately placed within the phantom and pin
pricked or otherwise marked at known locations. This, how-
ever, is insufficient to characterize the measured dose distri-
bution locations. A detailed understanding of the dose distri-
bution comparison software is also necessary to accurately
coregister the location of the dose measurement. Some dose
distribution comparison software does not provide the capa-
bility of an independent registration of the calculated and
measured dose distributions, but provides only relative reg-
istration. Relative registration involves selecting landmarks
in the calculated and measured dose distributions, necessitat-
ing that fiducial landmarks be placed on the calculated dose
distribution and either the film image or dose distribution.
This is often not possible for example, in phantoms where
the phantom localization fiducial markers are placed on the
outside of the phantom. In this case, care must be taken to
assure that the localizations of the film and phantom coordi-
nates are as independent as possible, as opposed to aligning
the two dose distributions based on only the dose, which
would be insensitive to an error in the dose distribution lo-
calization.
IV.B. Dose comparison tools
Van Dyk et al.161 were the first to publish on the impor-
tance of applying a particular dose distribution comparison
test based on the local dose gradient. In regions of shallow
dose gradient, the numerical differences between two com-
pared dose distributions provide an effective tool in deter-
mining whether the two distributions agree. However, in
steep dose gradient regions, the dose difference is very sen-
sitive to small spatial offsets and can show misleadingly
large discrepancies between the compared dose distributions.
This sensitivity leads to the concept of distance-to-
agreement, where the distance between steep dose gradient
regions is used as a determinate of dose distribution compa-
rability Fig. 4e. The sensitivity of dose comparison tools
as a function of local dose gradient has fostered development
of other dose comparison tools as well, some of which are
described in this report.
IV.B.1. Dose distribution overlays
A basic consideration of dose distribution comparisons is
to make them quantitative, yet allow the observer an efficient
evaluation of the results. Dose distribution overlays provide
a rapid overview of the two dose distributions Fig. 3 shows
an example of superimposed isodose distributions.162 The
individual dose distributions can be displayed as isodose
contours Fig. 3 or color bands. An isodose contour con-
nects regions within a dose distribution that share a common
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regions. Because isodose contours identify the location of a
specific dose level, for a given dose uncertainty, variation in
the contour position is greater in shallow than steep dose
gradient regions, so isodose contours of superimposed dose
distributions with constant dose distribution differences will
lie farther apart in regions of shallow dose gradients than
steep dose gradients. Typical graphical presentations of su-
perimposed isodose distributions do not discriminate with
respect to the local dose gradient, so such dose differences
are challenging to interpret.
This sensitivity of the isodose line position with respect to
the local dose gradient should be considered when superim-
posing two dose distributions. Often the selection of isodose
lines can make quantitative evaluation more efficient. For
example, selecting isodose lines that reflect the doses found
in the steep dose gradient regions aids in the assessment of
the relative locations of the gradients in the two dose distri-
butions. Conversely, selection of isodose contours near the
maximum dose, and consequently existing in shallow dose
gradient regions, may yield isodose contours that do not ap-
pear to match due to the sensitivity of contour positioning
with respect to small dose deviations. It is this feature that
limits the utility of superimposed isodose distributions for
dose distribution comparisons.
IV.B.2. Dose-difference distributions
The dose-difference tool displays the numerical difference
between two dose distributions. Figure 4 shows examples of
the dose-difference tool for the two dose distributions Figs.
4a and 4b, provided from Childress and Rosen162 shown
in Fig. 3. In this case, both absolute Fig. 4c and relative
Fig. 4d dose differences are shown. There are many
striped regions that exceed 3% in the periphery of the dose
distributions. These types of striped dose discrepancies are
often seen in cone-beam IMRT dose distributions. While the
FIG. 3. Superimposed dose distributions intended to compare IMRT dose
distributions. In this case, the solid and dashed lines are the calculated and
measured distributions, respectively. When the superimposed isodoses over-
lap, the reviewer can readily see that they agree. However, when the doses
differ, such as in the high-dose region in this example, a quantitative evalu-
ation is difficult. Reference is from Childress et al. Ref. 162.
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tween two dose distributions, it tends to be overly sensitive
in steep dose gradient regions.
Figure 5 shows comparisons between two mathematically
defined dose distributions163 that mimic 1010 cm2 6 MV
fields. One field is left intact the reference distribution,
while the second the evaluated distribution is divided into
four quadrants, each manipulated to highlight different char-
acteristics of the dose evaluation tools. The evaluated distri-
bution in quadrant 1 is identical to the reference distribution.
The evaluated dose distribution in quadrant 2 has been scaled
such that the dose varies by 6% at the field edges
1.2% cm−1 dose gradient. The evaluated dose distribution
in quadrant 3 has been shifted by 1.2 mm for each cm of
off-axis distance to mimic spatial discrepancies between
dose distributions. A combination of the dose gradient and
shift are applied in quadrant 4. For quadrants 2–4, the refer-
ence and evaluated dose distributions coincide along the cen-
ter of the field edge. For these examples, the acceptable dose
difference is 3%.
The dose difference for the fields shown in Figs. 5a and
5b is shown in Fig. 5c. In quadrant 1 where both dose
FIG. 4. Example of dose distribution evaluation and display tools. Examples
are from Childress and Rosen Ref. 162.Medical Physics, Vol. 38, No. 3, March 2011distributions are the same, the dose difference is uniformly
zero. In quadrant 2 dose gradient, the dose difference varies
smoothly in both steep and shallow dose gradient regions. In
quadrant 3 shift, the dose difference becomes large
20% even though the shifts are relatively small
6 mm because of the steep dose gradients. Even where
the shift is 2 mm, the dose differences exceed 3%. This
highlights the sensitivity of the dose-difference tool in steep
dose gradient regions.
IV.B.3. Distance-to-agreement
The DTA tool was developed to provide the user with a
measurement of the distance discrepancy between two dose
distributions.160,161 A typical application of the DTA tool is to
calculate the DTA value for each reference point by scanning
the evaluated distribution for the closest point that has the
same dose value as the reference point. This is equivalent to
determining the closest approach of the evaluated isodose
curve with the same dose as the reference point. In steep
dose gradient regions, this can be interpreted as the distance
between the two dose distributions. This interpretation is
based on the assumption that the distance is caused primarily
by a spatial offset between the two distributions. For distri-
butions that differ by such an offset, the DTA distribution
provides an effective and accurate measurement of the offset.
FIG. 5. Numerically defined dose distributions provided to illustrate dose
distribution comparison tools. Examples are from Low and Dempsey Ref.
163.However, the discrepancy may not be due to an error of the
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due to experimental error. While as originally described, the
DTA tool provides only the magnitude of the distance; the
sign of the dose difference can be added to the DTA. This
provides an indication of which of the two dose distributions
is greater. It can also be used to quickly determine if the
discrepancy is due to a spatial offset due to one distribution
being “larger” than the other.
Figure 4e shows the DTA for the example provided by
Childress and Rosen.162 In this case, the regions of large
DTA are located in the high-dose region, where the dose
gradient is shallow. Figure 5d shows the DTA for the ex-
ample from Low and Dempsey.163 For this example, the DTA
criterion is 3 mm. The DTA in quadrant 1 is zero, while in
quadrant 2, the DTA is small and large in steep and shallow
dose gradient regions, respectively. The DTA becomes
greater than 3 mm in the region where the dose discrepancy
is 1%, except in the steep dose gradient region. The DTA
tool is very sensitive in the shallow dose gradient regions,
but insensitive to even large dose differences 6% in steep
dose gradient regions where the spatial discrepancy of the
dose distributions is small. In quadrant 3, the DTA increases
as expected with the applied spatial dose shift of the evalu-
ated distribution. Because shallow dose gradient regions
dominate clinical dose distributions, the DTA tool typically
yields large regions where the DTA value is large but these
large values are not clinically relevant. This makes visual
interpretation of DTA distributions challenging.
IV.B.4. Quantitative comparison tools
The dose overlay, dose difference, and DTA distributions
provide good comparisons between the two distributions.
The remaining tools to be discussed require that the user
specifies acceptance or scaling factors that are used in the
comparisons.
IV.B.4.a. Composite tool. Due to the complementary sen-
sitivity of dose-difference and DTA tools, the composite tool
was developed160 to identify regions that disagreed by both
dose and distance. Acceptance criteria for the dose difference
and DTA are selected and the regions that exceed the criteria
in both dose difference and DTA are identified. These points
are said to fail the comparison, while the remaining points
pass and can be displayed as a binary distribution. Figure
5e shows an example of the composite tool for the case
shown by Low and Dempsey163 using dose and distance cri-
teria of 3% and 3 mm, respectively. In quadrant 1, the com-
posite tool passes in all locations. In quadrant 2, the compos-
ite tool passes when the dose difference is less than 3% or in
the steep dose gradient regions, where the DTA criterion
passes. In quadrant 3, the composite distribution passes ex-
cept for the steep dose gradient region where the applied
shift is 3 mm. Quadrant 4 shows failures that encompass
the regions shown in quadrants 2 and 3.
IV.B.4.b. Gamma and similar tools. While the composite
tool indicates the location of failure, it provides only a pass/
fail indication. There is no indication of the magnitude ofMedical Physics, Vol. 38, No. 3, March 2011failure. Having a quantitative measure of the degree of agree-
ment allows the user to develop a response appropriate to the
degree of disagreement.
Low et al.163,241 developed a tool that combines dose and
distance criteria in a single, quantitative test. The doses and
spatial coordinates are first renormalized by user-selected
dose and distance acceptance criteria. Because the resulting
quantities are unitless, they can be evaluated simultaneously.
The two dose distributions to be compared are assigned as
the reference and evaluated distribution. For each point in
the reference distribution, the normalized distance to each
point in the evaluated distribution is measured, where the
distance includes both normalized spatial and dose values.
The closest approach shortest distance of the reference dis-
tribution is identified as the  value. The  value is unity
when the closest approach of the reference distribution is on
the unit sphere. The unit sphere indicates the region within
which the comparison test passes. Therefore, if the reference
distribution pierces the unit sphere, the  test passes, other-
wise it fails. The  value can be displayed as a distribution
for evaluation. Figure 5f shows an example of the  distri-
bution for the two dose distributions shown in Figs. 5a and
5b, with scaling criteria of 3 mm and 3%. As a guide to the
eye, a contour is provided at the value of =1. The value of
 is zero in quadrant 1. In quadrant 2, the dose difference
exceeds 3% at an off-axis distance of 2.5 cm and this is
evident by the =1 contour. The value of 1 in the steep
dose gradient region is because the DTA is less than 3 mm in
this region. The value of  is dominated in this region by the
distance between the reference and the evaluated distribu-
tions. In quadrant 3,  is dominated throughout most of the
dose distribution by relatively small dose differences. This is
true except within the steep dose gradient region, where the
dose differences are large and the value of  is determined
by the spatial distance between the reference and the evalu-
ated distributions. The =1 contour appears in the region
where the spatial shift exceeds 3 mm the distance criterion.
A clinical example of the use of the tool is presented in
Fig. 6 Ref. 164 for the head-and-neck case. Figure 6a
shows the value of  with the superimposed calculated dis-
tribution. The example shows the regions that fail the criteria
3% and 3 mm in this case, highlighting areas of significant
failure. Stock et al.164 also identified the fact that the angle
FIG. 6. Example of the use of the  and  angle tools is from Stock et al.
Ref. 164.that the  vector makes to the spatial axes the complement
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determine whether the  discrepancy is due to a spatial or
dose error. An example of the  angle is shown in Fig.
6b.164 While the  angle may be useful in evaluating the
failure reasons, it is very sensitive to dose distribution noise
and can be difficult to visually evaluate.
The  tool has been successfully implemented in a num-
ber of dose comparison studies,12,123,133,165–174 and some au-
thors have proposed modifications to the tool to provide
more efficient calculations and to extend the capabilities of
the tool.162,164,167,175–178 One example is shown in Fig. 4f,
provided from Childress and Rosen162 based on their normal-
ized agreement test NAT. The NAT calculation is similar to
gamma, but is zero where the doses agree within acceptable
tolerances, so the comparison values are displayed only in
the regions that fail the comparison and are greater than 75%
of the prescription dose. This allows the user to focus on the
regions that failed and not be distracted by the regions that
passed the comparison tests.
One of the difficulties with the use of the  tool had been
the relatively large computation time and the requirement for
interpolation of the evaluated distribution when measure-
ments are widely spaced relative to the DTA criterion. Bakai
et al.175 proposed to use the acceptable local dose error and a
function called , which is computed more efficiently than ,
but yields very similar information. Figure 7 shows an ex-
ample from Bakai et al.175 where they compared a measured
and calculated dose distribution. They conducted both the 
and  tests in two and three spatial dimensions the measured
distribution was film, but the calculated distribution was in
three dimensions. The two-dimensional evaluation was un-
able to evaluate nearby out-of-plane points and therefore
overestimated both  and . They concluded that, when pos-
sible, the calculated dose distribution should be queried in all
three dimensions. Because  was signed, it was capable of
FIG. 7. Comparison between  and  as defined by Bakai et al. Ref. 175.Medical Physics, Vol. 38, No. 3, March 2011assisting in the evaluation of two shifted dose distributions,
although the definition of  can be slightly modified to ac-
count for the sign of the dose difference. A new, recursive
method for computing  was recently developed by Ju et al.,
that significantly improves  computation, speed, and
accuracy.240
Another tool uses a gradient-compensation method.179
The local dose gradient for each point in a distribution is
calculated in 2D or 3D. Then, the user selects a distance
parameter typically 1 mm to account for potential errors
due to geometric uncertainties such as film alignment and
calculation grid size e.g., one-half of the grid size. The dose
gradient at each point is then multiplied by the distance pa-
rameter to determine the gradient compensated distribution.
Dose differences that are not explained by the gradient com-
pensation remain and are displayed with an isodose color
wash. This method is used in conjunction with standard dose
evaluation methods to highlight differences that may be due
to systematic discrepancies between calculations and mea-
surements.
IV.C. Summary
No single dose comparison tool provides all of the infor-
mation necessary to quantitatively evaluate or compare dose
distributions. Each tool has limitations that need to be under-
stood when conducting evaluations. The most basic dose
overlay method requires that the user interpret the differ-
ences themselves, relying on visually detecting regions
where the doses differ. The dose-difference tool is a very
intuitive tool, but has the limitation that very large dose dif-
ferences can be caused by relatively small spatial discrepan-
cies in steep dose gradient regions including coregistration
errors. Given its quantitative and intuitive nature, however,
the dose-difference tool should be employed when other
tools, such as the  tool, indicate a discrepancy. Tools, such
as the  tool, that integrate more than one type of discrep-
ancy evaluation are useful when a large amount of dose data
needs to be reviewed quickly, such as for routine patient QA.
When discrepancies are identified, the clinical impact of
those discrepancies can be determined using the dose-
difference tool. Dose analysis tools such as  and the gradi-
ent tool should be used to evaluate measurements compared
to 3D calculations for completeness. These analysis tools are
best applied to data with limited noise.
V. ADDITIONAL SYSTEMS FOR QUALITY
ASSURANCE
V.A. Electronic portal imaging devices
EPIDs have been designed for verification of patient po-
sition and are mounted to the treatment gantry. However, the
ability to acquire 2D electronic data in the machine geometry
have led to the investigation of EPIDs for verification of
individual leaf position,180,181 radiation vs light field checks,
and IMRT field verification. Commercial EPIDs include
charge-coupled camera devices CCD, scanning liquid ion-
ization chamber, and active matrix flat panel imagers AM-
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plications with AMFPIs. van Elmpt et al.182 reviewed the
different approaches for using EPIDs for radiation therapy
dosimetry applications. The primary investigations have
been for EPID systems incorporating a scintillator where in-
direct detectors are used.183–186 Corrections are made to a
system that has been optimized for imaging. Additional in-
vestigations have been conducted for prototype and systems
modified from a commercial configuration where there is no
scintillator above the detector and measurements are made in
a direct detection mode.187–190
V.A.1. Application to IMRT
EPIDs offer the potential to save time when compared to
film dosimetry. They offer a finer spatial resolution than ar-
ray devices. However, the application of EPIDs to IMRT is
limited to measurements of individual fields and EPIDs can-
not be placed in a solid water stack. For all of the EPID
systems, a number of corrections must be applied to convert
the resulting signal into fluence or dose in the detector.
EPIDs have been used for pretreatment and transit dosim-
etry applications. In the pretreatment configuration, the ex-
pected response of the EPID is typically determined at the
plane of the detector as a portal dose image.183–186 The re-
sponse of the EPID is then converted to dose and compared
to the predicted dose image. Quantitative dosimetric mea-
surements for IMRT fields have also been made with systems
using a direct detection mode.187,190 For clinical dosimetry
applications, the system needs to be validated against refer-
ence dosimeters of appropriate accuracy and resolution. The
other application of EPIDs is for transit dosimetry where
measurements are made during a patient’s treatment and
used to evaluate the accuracy of the delivery considering the
patient’s geometry.191–193 The use of EPIDs for transit dosim-
etry continues to be an important research topic with the
potential for providing important real-time information about
the accuracy of the delivery of IMRT treatments.
V.A.2. Recommendations for use
Once an IMRT program has been started with ion cham-
ber and film measurements, it may be appropriate to use an
EPID for individual IMRT field verification measurements if
a reliable method of operation has been developed. The
EPID response must be characterized for a range of situa-
tions e.g., dose, dose rate, field size, and leaf speed. Once
the system is characterized, a number of corrections must be
made to the system depending on the type of system and the
composition of the detector. The presence of a fluorescent
screen leads to an over-response of the detectors to low
doses. To calculate a portal dose prediction or portal dose
image for AMFPI systems, pencil beam,185 convolution,183 or
Monte Carlo194 techniques have been used to approximate or
model the interactions in the EPID including the effect of the
fluorescent layer.
Some centers are utilizing commercial systems for IMRT
dosimetry. When establishing a QA program with an EPID,
the sensitivity of the system and the appropriate action levels
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ment of EPIDs for individual IMRT field verification and for
patient transit dosimetry is expected to continue.191–193,196–200
Exciting developments include reconstruction of three-
dimensional dose distributions.201
V.B. Three-dimensional detectors
Truly comprehensive dosimetric verification of IMRT re-
quires a dosimetry system with full capability in 3D. Tradi-
tional 2D verification techniques e.g., film, and the more
recent 2D array detectors discussed above, present at best a
partial sampling of the whole distribution. Partial sampling
may be adequate as a routine check for an IMRT program
that has extensive prior validation. In the general case, how-
ever, and in particular for the commissioning of a new IMRT
technique, an extensive 3D dosimetry technique is highly
desirable. The criticality of this issue is exemplified by a
recent report from the Radiological Physics Center RPC,202
which revealed that between 2001–2009, more than 350 in-
stitutions failed to pass the head-and-neck IMRT credential-
ing phantom test on the first attempt, despite generous crite-
ria 7% dose difference and 4 mm distance-to-agreement.
The RPC criteria were applied to TLD measurements at six
points inside the simulated planning-target-volume PTV
and GAFCHROMIC® film measurement in a single axial
plane through PTV and organ-at-risk. The question arises—
what percentage of institutions would have failed if a more
comprehensive 3D measurement had been feasible rather
than measurements restricted to the central film plane and
TLD points? This question can only be adequately answered
if the measurement is a comprehensive verification in 3D and
presents a compelling argument for the need for a clinical 3D
dosimetry system. A relatively new technology with the ca-
pacity to address this need and provide high-resolution, ac-
curate 3D dosimetry has emerged under the initial name of
“gel-dosimetry.” In this report, we will use the term “3D
dosimetry” to reflect the fact that some new 3D dosimeters
are no longer gel-based.
A goal of 3D dosimetry has been formulated in the
resolution-time-accuracy-precision RTAP criteria.203 The
RTAP ideal functionality incorporates a spatial resolution of
1 mm3, short read-out time of 1 h, accuracy within 3% of
true value, and a noise level within 1%. Several dosimetry
systems are approaching this goal, and the field of 3D do-
simetry continues to accelerate in innovation and promise.
Recently, new 3D dosimetry materials have been proposed
with striking performance characteristics.204,205 The three
principal categories of 3D dosimeters are polyacrylamide
PAG gels,206 Fricke gels,204 and radiochromic plastics,205
and the two main methods of dose-readout are magnetic
resonance MR imaging207,208 and optical-computed-
tomography optical-CT.203,204,209 Other readout techniques
are under evaluation, including x-ray-CT and ultrasound, but
are not discussed further here as they are more preliminary.
V.B.1. Polymerizing gels
The original PAG gel206 consisted of bis 3%, acrylamide
3%, nitrogen, and gelatin 5% by weight. Newer formula-
1332 Low et al.: IMRT dosimetry tools 1332tions are more radiation sensitive210 and can be made under
conditions of normal oxygenation.210 PAGs utilize the
mechanism of radiation-induced polymerization of mono-
mers, where small monomer molecules join together under
the influence of ionizing radiation.211 The resultant polymer
microparticles are fixed in the gelatin lattice, yielding a
stable impression of the dose. Below saturation, regions of
the gel exposed to ionizing radiation exhibit polymerization
in proportion to the dose, and the polymerization affects both
the MR relaxivity of water protons and also the optical scat-
tering power of the gel. High resolution 3D maps of dose
have been achieved both by MR scanning and optical-CT
scanning Sec. V B 3. Initial applications to IMRT verifica-
tion have been promising.64,210,212–217
V.B.2. Fricke and radiochromic gels and plastics
The first gel dosimeter arose from the work of
Gore et al.,218 who proposed that the well established liquid
Fricke dosimeter219,220 could be gelated and probed by
nuclear magnetic resonance imaging MRI rather than the
conventional spectrophotometry. The addition of a stabiliz-
ing gelatin matrix to the aqueous Fricke solution created the
first gel dosimeter, where 3D MRI images of the T1 relax-
ation parameter showed the relaxation rate 1 /T1 proportional
to the absorbed dose. A limitation of gelatin Fricke dosim-
eters is that the radiation-induced ferric ions diffuse through
the gel matrix, leading to degradation and eventual loss of
the recorded dose distribution with time.221,222 The practical
implication is that Fricke gel dosimeters must be scanned
within 2 h postirradiation, presenting logistical difficulties in
a clinical setting. Most Fricke gel dosimetry has utilized MR
as the readout method; however, Kelly et al.204 introduced
xylenol-orange dye to create a Fricke gel compatible with
optical-CT imaging. Recently, a promising new radiochromic
material, PRESAGE,223 has been introduced and detailed
studies of the basic dosimetric properties have confirmed its
promise for 3D dosimetry.224 Principal advantages include
relative insensitivity of dose response to atmospheric expo-
sure and to the nature of radiochromic optical contrast that is
light absorbing rather than light-scattering peak OD change
is at 633 nm. The absorptive nature of the contrast is
more amenable to accurate dose read-out by optical-
computed-tomography optical-CT.225–227
V.B.3. Readout techniques
To date, most gel dosimetry has utilized MR scanning,
which can yield excellent results, provided sufficient care is
taken to characterize the MR scanner and implement appro-
priate sequence protocols.64,207,228–230 In particular, attention
is required to minimize uncertainties that originate from the
technical challenges of controlling magnetic field uniformity
and gradients with sufficient precision, avoiding MRI se-
quences that cause excessive temperature increase associated
with RF energy deposited in the gel during MR imaging.228
For MR measurements requiring high accuracy and high-
spatial resolution, long imaging times several hours may be
required to achieve the low uncertainty and high spatial res-
Medical Physics, Vol. 38, No. 3, March 2011olution associated with standard dosimeters. An alternative
readout technique, optical-CT,166,203,204,209,227,231–235 has been
proposed for imaging PAG gels; an approach analogous to
first-generation x-ray CT. In optical-CT the x-ray source is
replaced by a visible laser and the x-ray detector replaced
with a light-sensitive photodiode. Resonstructed images of
optical attenuation coefficients are proportional to dose and
can be converted to dose maps using a calibration curve. The
high proportion of scatter in PAGs restricts optical-CT to
slow first-generation scanning-laser configurations. Much
faster broad-beam and cone-beam configurations have been
developed for radiochronic gels and plastics, where the scat-
ter component is much less.232,237 For these approaches cor-
rections may be necessary for spectral warping238 and re-
sidual scatter.232,239
V.B.4. Recommendations for use
The 3D dosimetry techniques described here are still in
the developmental stage and should be embarked upon with
that understanding in mind. Commercial support for these
techniques, while expanding, is still limited. At present, the
only commercially available system is the BANG gel system
from MGS Research. This polymer-gel/optical-CT readout
system has been shown to be effective166,217,236 and is avail-
able as a remote dosimetry service by the gel manufacturer.
Detailed specifications on the accuracy of system perfor-
mance of the remote system are not available at present.
There are other dosimetry materials and readout techniques
that can be employed. Each has strengths, but also areas
where care must be taken to get adequate results. If MR
scanning is to be used, the performance and sequences of the
MR scanning system should be investigated first. Similarly,
the performance characteristics of optical-CT systems need
to be thoroughly evaluated prior to use. For all present 3D
materials, it is important that the dose calibration curve is
generated from the same batch and undergoes the same ther-
mal and temporal histories as the experimental dosimeter.
VI. SUMMARY
This report provides information to the physicist regard-
ing the proper applications of different dosimeters, phan-
toms, and analysis techniques for IMRT dose distributions.
The detectors and phantoms used in commissioning an IMRT
program are frequently not the same systems used for pre-
treatment quality assurance applications. This report also
provides guidance on the potential pitfalls by highlighting
areas where certain systems are inappropriate for use. When
establishing a new IMRT program, this information should
be used in conjunction with other guidance documents on
IMRT.
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